Cyclacel Pharma (CYCC) Tops Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
- Qualcomm shares fall on Intel warning and legal concerns
- Marvell Technology shares drop on Lumentum deal concerns
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Oracle shares drop on AI spending concerns and Microsoft criticism
- SpaceX stock drops on launch setback and sector selloff
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
August 10, 2022 4:05 PM EDTÂ - Oral fadraciclib demonstrated good tolerability with continuous dosing;Â anticipate entering Phase 2 POC stage in 2H 2022
         - Demonstrated evidence of target engagement for CDK2 and CDK9
         - Company to host R&D day in fall of 2022 to highlight data updates          for fadraciclib and CYC140 in solid tumor Phase 1/2 studies
         - Cash runway into 2H 2023 -
               - Conference call scheduled for August 10, 2022 at 4:30 pm... More



